glucagon

Glucagon (1-29), bovine, human, porcine 是由胰腺 α 细胞产生的一种具有胰高血糖素活性的激素，可促进糖原分解和糖异生化，可用于研究肥胖和糖尿病。

Glucagon 对蛋白质和氨基酸的代谢产生显著的调节作用。它抑制了氨基酸与肝脏、肌肉以及胰腺蛋白的结合，增加氮的排出，并促进肝脏内尿素的合成。同时，Glucagon 增加了肝脏中转氨酶和尿素循环酶的浓度，提高了肝脏对氨基酸的摄取，并加强了氨基酸与肝糖原之间的结合，从而降低了血液中的氨基酸浓度。

LGD-6972 是口服有活性的胰高血糖素受体选择性拮抗剂，能够用于研究 2 型糖尿病。

Saxagliptin hydrate (Onglyza hydrate) 是一种选择性，竞争性，可逆性和口服活性的二肽基肽酶 4 (DPP-4) (Ki= 0.6-1.3 nM) 抑制剂。Saxagliptin hydrate 能够用于 2 型糖尿病的研究。

PF-06291874 (Glucagon receptor antagonists-4) 是口服有活性的胰高血糖素受体非肽类拮抗剂。它正用于研究 2 型糖尿病。

AZD-1656 是口服有效的葡萄糖激酶选择性激活剂，EC50为 60 nM。AZD1656在2 型糖尿病中有研究的价值。

Glucagon receptor antagonist -1 is a highly effective glucagon receptor antagonist.

Glucagon receptor antagonist -3 is a highly effective glucagon receptor antagonist.

Glucagon receptor antagonists-5 is an orally bioavailable indazole-based glucagon receptor antagonist (Ki: 32 nM). It has potential for the treatment of type 2 diabetes mellitus (T2DM).

Glucagon Receptor Antagonist Inactive Control 是一种 Glucagon 受体拮抗剂，可用于生命科学领域的相关研究。其产品编号为 T36580，CAS号为 362482-00-6。

[Des-His1,Glu9]-Glucagon amide TFA is a potent peptide antagonist targeting the glucagon receptor, featuring a pA2 value of 7.2. It holds potential utility in diabetes pathogenesis research[1].

Glucagon receptor antagonist I is a competitive antagonist of the glucagon receptor (GCGR; IC50 = 181 nM). It blocks glucagon-induced glycogenolysis in primary human hepatocytes and isolated liver. Glucagon receptor antagonist I, at 50 mg/kg, reduces the increase in glucose levels observed after intraperitoneal administration of glucagon in humanized mice. Glucagon receptor antagonist inactive control does not prevent glucagon-mediated actions.

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human 是一种被 C 端标记的生物素化 GLP-1(7-36) 酰胺。

[Des-His1,Glu9] Glucagon 是一种有效的胰高血糖素受体系统多肽拮抗剂。[Des-His1,Glu9] Glucagon 增强胰岛细胞在葡萄糖刺激下释放胰岛素。[Des-His1,Glu9] Glucagon 可用于糖尿病的研究。

Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide 是一种带有生物素标签的Glucagon-like peptide-1-(7-36)，后者为一种具备提升胰岛素释放功能，从而表现出抗糖尿病活性的胃肠道肽。

Biotinyl-Glucagon (1-29), human, bovine, porcine 为带生物素标记的Glucagon衍生物，此肽类激素由胰腺α细胞分泌，功能是提升血液中的葡萄糖与脂肪酸浓度。

'(Met(O)27)-Glucagon (1-29) (human, rat, porcine) 为修饰版胰高血糖素。在大鼠肝细胞内，其促进葡萄糖合成的活性虽与天然胰高血糖素相似，但呈现出较低效率，暗示蛋氨酸对于胰高血糖素与其肝脏受体绑定具有关键性作用。'

Glucagon (22-29) 作为Glucagon (19–29)的部分激动剂，能特异性抑制肝质膜 Ca2+泵，其作用机制与腺苷酸环化酶激活无关。

'(Asp28)-Glucagon (1-29) (human, rat, porcine)' 为胰高血糖素的一种改良型结构，在第28位氨基酸残基上天冬氨酸（Asp）替换原有残基，显著提高了该化合物在生理pH条件下的溶解性，且保持了与天然胰高血糖素相同的生物活性。

Glucagon, a peptide hormone derived from proglucagon in pancreatic α cells, regulates glucose metabolism. It stimulates glucose production in rat hepatocytes ex vivo and enhances glucose output from perfused rat livers through elevated gluconeogenesis and glycogenolysis, while reducing glycolysis, and raises plasma glucose levels in rats. Glucagon secretion decreases following food intake in healthy rats and humans, yet remains unchanged or increases in individuals with type 2 diabetes.

Glucagon-like peptide 1 (1-37), human (TFA), is a highly potent agonist of the GLP-1 receptor and is a pancreatic hormone synthesized through post-translational processing of proglucagon.

Glucagon-like peptide 1 (1-37), human, is a highly potent agonist of the GLP-1 receptor and a pancreatic hormone synthesized through post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats.

Glucagon-like peptide 1 (1-37), human acetate 是一种高效的 GLP-1 受体激动剂。

Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently Glucagon-Like Peptide 2 is used as a po